Long Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART)

Sponsor

Istituto Auxologico Italiano (Other)

Overall Status

Recruiting

CT.gov ID

NCT05781269

Collaborator

(none)

100

Enrollment

Location

Arms

58.3

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The growing obesity pandemic has a major impact on global cardiovascular (CVD)-related morbidity and premature mortality, severely compromising the quality of life of those affected and significantly increasing costs for the healthcare system.

Numerous scientific evidences have demonstrated that a moderate weight loss (5-10% of the initial body weight) is already sufficient to determine the improvement of the cardiometabolic risk factors associated with overweight and obesity. With a view to obtaining a more significant weight loss in the initial stages of dietary treatment, in the last 10 years, the very low-calorie ketogenic diet (VLCKD) has become a strategy for the treatment of obesity and its comorbidities, also allowing to limit therapeutic failure and the high drop-out typical of traditional low-calorie diets.

One hundred subjects with severe obesity and metabolic syndrome will be recruited and randomly assigned to VLCKD or to restrictive Mediterranean diet. Anthropometric parameters, metabolic status blood pressure, degree of arterial stiffness, prevalence and severity of snoring and OSA, cardiac systolic and diastolic function, the autonomic nervous control mode of the circulation will be evaluated at baseline, after one month and at the end of the study.

Condition or Disease	Intervention/Treatment	Phase
Obesity Morbid Obesity	Other: VLCKD Other: r-MedDiet	N/A

Detailed Description

The present study aims to study the long-term efficacy (36 months) of VLCKD in patients with severe obesity and metabolic syndrome, on weight loss, on single factors of the metabolic syndrome, on the plasma concentration of specific adipokines and myokines on the properties of arterial wall, cardiovascular function, and sleep quantity and quality compared to a restrictive Mediterranean diet.

The studied population includes men and women between the ages of 55 and 75, with no documented history of CVD, severely obese (BMI ≥30 e <50 kg / m2) and at least three positive factors for metabolic syndrome. The patient, after consideration of inclusion and exclusion factors, are enrolled for 36 months and randomly divided into two groups (50 patients for group): group 1 is assigned to VLCKD diet treatment with medical food (VLCKD-group) whereas group 2 followed Mediterranean diet treatment (r-MedDiet). Medical Foods products are provided by Therascience. For both groups, the achievement of the objective is set as a variation of 20% compared to the initial weight. Throughout the study, the long-term efficacy of VLCKD compared with a restrictive Mediterranean diet will be evaluated on the modification of anthropometric parameters (weight, waist circumference, hip circumference, impedance test) metabolic status (using blood chemistry tests for the evaluation of Blood glucose, glycosylated hemoglobin, insulin, total cholesterol, HDL, triglycerides, adiponectin and irisin), blood pressure (by sphygmomanometer), degree of arterial stiffness (by Pulse Wave Velocity carotid-femoral), prevalence and severity of snoring and OSA (by polysomnography), cardiac systolic and diastolic function (by three-dimensional echocardiography), the autonomic nervous control mode of the circulation (by analysis HRV, Arterial Baroreflex Sensitivity). .

These evaluations will be carried out at pre-established and different times (T0-T22) during the entire duration of the study.

The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement. The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Metabolic Syndrome and Severe Obesity: Randomized Nutritional Trial to Study Long Term Effect of Very-low-calories Ketogenic Diet (VLCKD) on Weight Control and Cardiovascular Risk Factors

Actual Study Start Date :

Feb 20, 2022

Anticipated Primary Completion Date :

Dec 31, 2026

Anticipated Study Completion Date :

Dec 31, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: VLCKD-group The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.	Other: VLCKD VLCKD diet treatment with medical food
Experimental: r-MedDiet The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement	Other: r-MedDiet Mediterranean diet treatment

Arm

Intervention/Treatment

Experimental: VLCKD-group

The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.

Other: VLCKD

VLCKD diet treatment with medical food

Experimental: r-MedDiet

Other: r-MedDiet

Mediterranean diet treatment

Outcome Measures

Primary Outcome Measures

change from baseline body weight at 36 months [baseline, 36 month]
body weight measured to the nearest 0.1 Kg with a calibrated weight scale
change from baseline fasting glucose in mg/dl at 36 months [baseline, 36 month]
blood chemistry tests for the evaluation of blood glucose
change from baseline HDL cholesterol, triglycerides at 36 months [baseline, 36 month]
blood chemistry tests for the evaluation of HDL cholesterol, triglycerides
change from baseline blood pressure in mmHg at 36 months [baseline, 36 months]
measurement of systolic and diastolic pressure using using an aneroid sphygmomanometer with the appropriate cuff
change from baseline distensibility of the carotid, radial and femoral arteries in m/s at 36 months [baseline, 36 months]
arterial stiffness measured by Pulse Wave Velocity carotid-femoral
change from baseline waist circumference in cm at 36 months [baseline, 36 months]
waist circumference using a non-stretch tape to the nearest 0.5 cm

Secondary Outcome Measures

change from baseline total and LDL cholesterol in mg/dl at 36 months [baseline, 36 months]
blood chemistry tests for the evaluation of total cholesterol, LDL cholesterol
change from baseline % of subjects with obstructive sleep apnea at 36 months [baseline, 36 months]
apnea hypopnea index using polysomnography
change from baseline cardiac systolic and diastolic function at 36 months [baseline, 36 months]
evaluation of the cardiac systolic and diastolic function using by three-dimensional echocardiography
change from baseline autonomic nervous control mode of the circulation at 36 months [baseline, 36 months]
by analysis HRV, Arterial Baroreflex Sensitivity
change from baseline insulin in mU/ml at 36 month [baseline, 36 months]
blood chemistry tests for the evaluation of insulin
change from baseline glycated hemoglobin in mmol/mol at 36 month [baseline, 36 months]
blood chemistry tests for the evaluation of glycated hemoglobin

Eligibility Criteria

Criteria

Ages Eligible for Study:

55 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Men between the ages of 55 and 75 with no documented history of CVD (except NYHA class I and II heart failure or valvular heart disease)
Women aged 60 to 75, with no documented history of CVD (except NYHA class I and II heart failure or valvular heart disease)
BMI ≥30 and <50kg/m2-At least three positive factors for metabolic syndrome according to the harmonized definition (IDF --------2009)
Availability to be followed in the follow-up at the San Michele Hospital IRCCS Istituto Auxologico Italiano in Milan

Exclusion Criteria:

Long QT >0.44 s, known arrhythmia, cardiomyopathy, heart failure (NYHA classes III-IV)
Hypokalemia, hypernatremia
Persistent diarrhea
Acidosis (metabolic or respiratory) even if compensated
Acute heart failure, transient ischemic attack or stroke in the previous 12 months
Pregnancy or breastfeeding
chronic renal insufficiency (creatinine >1.5 and/or creatinine clearance <45 mL/min), history -positive for previous episodes of acute renal failure
Autoimmune diseases (TCA relative contraindication)
History of previous pancreatitis
Symptomatic cholelithiasis
Hepatic insufficiency and/or ALT and AST > 3 times the upper limit
Stubborn constipation or history of intestinal occlusions/subocclusions
Type 1 diabetes
History of previous cancer within the first 5 years of follow-up
Active eating disorder or history of bulimia and anorexia nervosa, active severe binge eating,
Psychiatric disorders not in compensation or at risk of decompensation
Alcoholism, substance abuse
Ongoing pharmacological therapy with topiramate, zonisamide, acetazolamide, valproic acid- - ----- - chronic therapy with diuretics (which cannot be suspended even temporarily), SGLT2 -inhibitors (due to the risk of euglycemic diabetic ketoacidosis) and beta blockers.
Known primary pathologies of carnitine metabolism or beta oxidation